Tharimmune, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THAR research report →
Price Chart
About the company
Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. Its preclinical immuno-oncology portfolio includes several product candidates: TH104, aimed at treating inflammatory conditions linked to the liver and other causes of itching; TH3215 and TH0059, which are designed to address a variety of solid tumors; and TH1940, specifically targeting programmed cell death protein 1 (PD-1).
- CEO
- Mark Wendland
- IPO
- 2022
- Employees
- 2
- HQ
- Bridgewater, NJ, US
Get TickerSpark's AI analysis on THAR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $139.94M
- P/E
- -1.41
- PEG
- -0.01
- P/S
- 113.94
- P/B
- 1.05
- EV/EBITDA
- -1.52
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -3595.17%
- Net Margin
- -6559.27%
- ROE
- -29.54%
- ROIC
- -8.14%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-20,106,066
- Net Income
- $-35,916,250-194.5%
- EPS
- $-1.12+88.1%
- OCF Growth
- -47.9%
- FCF Growth
- -47.9%
- 52W High
- $9.08
- 52W Low
- $0.95
- 50D MA
- $3.47
- 200D MA
- $2.73
- Beta
- 1.45
- RSI (14)
- 42
- Avg Volume
- 850.30K
No earnings-call transcripts are available for THAR yet.
- Free Float
- 73.1%
- Shares Outstanding
- 39.53M
- Float Shares
- 28.90M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 24 ETFs
Biggest fund positions in THAR by dollar value.
Our THAR coverage
Recent articles, reports, and earnings notes.
No research on THAR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate THAR report →Tharimmune Highlights Canton Network Q1 Growth, Tokenomics Shift and Validator Locking in Webinar
defenseworld.net · Apr 27
Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy
prnewswire.com · Feb 17
Catherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio Impact
gurufocus.com · Feb 11
Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer
prnewswire.com · Feb 6
Tharimmune Elects Jill Sommers and William Wiley to Board of Directors
prnewswire.com · Feb 2
Tharimmune Shareholders Approve Directors, Warrant-Linked Share Issuances and 7M Share Plan Boost
defenseworld.net · Jan 31
Tharimmune Announces Expanded Role as Super Validator on Canton Network
prnewswire.com · Jan 26
Tharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization
seekingalpha.com · Jan 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.